highlight organ sale growth vs target reflect continu
strength libr mitraclip alin manag increas guidanc
organ sale growth ep respect believ
continu post above-consensu result thu reiter
outperform rate rais target
base strength rais organ sale growth ep guidanc
specif compani increas organ sale growth guidanc
previous ep guidanc
previous anticip upward revis guidanc reiter
full-year target april despit strong perform keep manag
conserv approach set expect show confirm favor
trend seen stock respons quarterli result guidanc increas
move wednesday indic well receiv weve note must
lap strong quarterli perform year comp dynam
key concern investor domin discuss compani sever
quarter think help underscor strong multi-year growth potenti libr
mitraclip alin still face major near-term catalyst therefor
remain construct stock despit comp valuat increas
past month rais ep reiter
outperform rate increas price target target reflect
price-to-earnings multipl appli project ep forecast still addit
use discount cash flow sum-of-the-part valuat approach
perform highlight organ sale growth
recap abt revenu total vs street expect revenu
improv organ basi compani guidanc organ
sale growth around street forecast nutrit sale
top street consensu repres organ growth
diagnost sale also beat street forecast reflect organ growth
epd sale match street expect organ growth
sale medic devic shi consensu forecast vs
organ continu recent strength shown divis
organ growth quarter adjust gross margin exceed
guidanc offer lastli adjust ep came better
estim share street exceed guidanc rang
provid compani also introduc ep guidanc
vs street current forecast expect organ sale growth
foreign exchang neg impact around report sale
adjust gross margin littl less sale adjust
sg around sale respect
pleas see page report import disclosur
spin-out proprietari pharma new redux pre-humira
larg diversifi medic product compani competit global franchis
nutrit diagnost medic devic intern brand gener pharmaceut
post-spin ad st jude medic aler busi divest
advanc medic optic unit next five year believ combin abt/stj/
alr busi pois deliv revenu growth ep growth
low mid-teen make standout perform compar medic devic peer
believ may upsid estim potenti out-performance busi
unit better-than-expect contribut stj pipelin product success
business-develop initi blend valuat analysi dcf sum-of-the-part
price-to-earnings support outperform rate expect share outperform market
next month
fda approv libr
decis libr
increas market adopt mitraclip
 roll-out alin
gross oper margin expans
next five year
 enhanc product
acceler diagnost unit
stronger stj synergi captur alr
acceler recoveri intern
hsd revenu mid-dd ep growth
persist emerg market headwind
nutrit
franchis four major health care segment one diversifi
large-cap medic devic compani world offer lead product
nutrit diagnost medic devic establish brand gener pharmaceut
approxim compani revenu gener unit state
anoth come western europ canada japan australia remain
emerg market includ india china russia brazil januari
complet separ proprietari research-bas pharmaceut busi
oper independ large-cap pharmaceut compani
valu proposit libr full display confid remain high icgm approv
libr
freestyl libr post global sale repres stellar organ
growth rate importantli libr also reimburs approxim
 privat pharmaci benefit insur popul continu invest libr
manufactur capac first wave expans come on-line next
month follow increment capac add thereaft libr fda approv
manag reiter confid time approv still consist
intern timelin addit note fda encourag file
libr icgm would submit devic approv
met agenc clearli defin threshold accuraci alarm sensor shutoff etc
without quantifi precis peak sale figur libr manag acknowledg
mass market appeal product diabet demonstr
compel combin afford clinic efficaci also categories/
analyt may benefit capabl wearabl devic
mitraclip provid addit growth layer
structur heart reach mid-teen growth led continu expans
mitraclip record sale growth global
addit note growth primarili result increas
util exist account result follow announc earlier week
fourth-gener mitraclip devic receiv approv offer
physician new clip size enhanc featur includ altern leaflet grasp
featur independ control gripper allow physician grasp one
leaflet procedur control gripper actuat facilit procedur
assess real time describ long-term outlook mitraclip cite
devic low-single-digit penetr rate give compani confid
product sustain long-term growth driver reimburs
mitraclip function mr indic expect end year earli
latest approv could provid addit acceler product alreadi grow
healthi pace
 alin approv highlight potenti platform
diagnost alin continu attract strong demand specif european core
lab advanc phase roll-out immunoassay clinic
chemistri system manag state system place run
test europ recent receiv ce mark approv alin autom
molecular diagnost system enabl laboratori address grow demand
infecti diseas test earli stage launch instrument
hematolog molecular test custom europ earlier month receiv
fda approv alinitiy diagnost system featur sever blood plasma
screen assay compani anticip broader menu china
southeast asia enabl alin even signific
impact revenu start continu like alin roll-out believ
potenti tremend long-term growth driver
compani report thomson eikon cowen compani
consensu chg establish lab molecular poc medic cv rhythm manag heart structur diabet medic diversifi medic good gross gross margin oper net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper dilut share estimatesactu cowen
compani report thomson eikon cowen compani
chg pharma nutrit ww nutrit ww nutrit ww cardiovascular neuromodul ww rhythm manag ww electrophysiolog ww heart failur ww vascular ww structur heart ww neuromodul ww ww diagnost ww diagnost ww diagnost ww actualsour estim cowen
compani report thomson eikon cowen compani
good gross gross margin oper interest interest net interest expens currenc hedg expens net expens pre-tax incom tax incom tax net incom continu restructur non-recur charg net incom continu oper restructur non-recur charg dilut share analysisgross end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
laboratori diagnost laboratori diagnost molecular diagnost point diagnost point diabet revenu rhythm manag heart failur rhythm manag heart cardiovascular structur heart cardiovascular structur revenu end decemb end decemb end decemb cowen
compani report thomson eikon cowen compani
adjust good adjust gross adjust gross oper incom oper incom interest expens interest net interest expens currenc hedg loss expens net expens pre-tax incom incom tax incom tax net incom adj net incom oper net incom oper ep continu oper ep discontinu oper changeadjust ep oper includ disc ep oper share analysisgross incom -oper cowen
compani report thomson eikon cowen compani
 exclud ww sale exclud pharma exclud exclud ww sale exclud devic rhythm manag heart failur exclud ww rhythm manag heart ww sale exclud cardiovascular structur heart exclud ww ww sale exclud neuromodul exclud ww ww sale exclud neuromodul exclud ww stj ww sale exclud diabet exclud ww diabet ww sale exclud devic exclud ww medic ww sale exclud revenu exclud ww ww sale exclud total revenu exclud ww sale exclud total revenu pro-forma stj alr exclud ww sale exclud cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
competit dynam global potenti regulatori delay potenti delay
time product launch emerg develop market econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend share repurchas fluctuat foreign exchang rate
risk includ stj alr integr global competit pressur adult
pediatr nutrit busi price pressur procedur volum pressur
stent busi vascular product regulatori time approv mitraclip
 risk time regulatori approv meet demand
hundr product launch emerg market establish pharmaceut
busi meet growth target develop emerg market
meet target margin improv four major segment
